Oncolytics Biotech (ONCY) 1.26 $ONCY
Oncolytics Biotech® Inc. Announces First Quarter 2014 Results
CNW Group - Thu May 08, 5:30AM CDT
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company"
today announced its financial results and operational highlights for the first quarter ended March 31, 2014.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Finding People's Purpose In High-Tech Workplaces
at Investor's Business Daily - Wed May 07, 12:43PM CDT
No matter what field you're in, you're in the people business. So says Avner Gal, CEO of Integrity Applications, maker of GlucoTrack, a device that clips onto the ear to measure glucose levels in the blood without pricking the skin. "I am in this...
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Oncolytics Biotech Inc. Collaborators Present Preclinical Research on Liver Cancer at UK Oncolytic Virus Conference
PR Newswire - Mon Apr 14, 5:45AM CDT
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Combined anti-viral and anti-tumour therapy for virus-associated liver cancer," covered preclinical research into the treatment of hepatocellular carcinoma (HCC) associated with infection by Hepatitis B (HBV) and Hepatitis C (HCV).
Oncolytics Biotech Inc. Collaborators Present Head and Neck Cancer Biomarker Preclinical Research at UK Oncolytic Virus Conference
PR Newswire - Mon Apr 14, 5:30AM CDT
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC) (NASDAQ:ONCY) today announced that a poster authored by Bolton, et al was presented at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Resistance to oncolytic reovirus is associated with high expression of Yes-Associated Protein (YAP-1) in head and neck cancer," covered preclinical research focused on identifying biomarkers predictive of sensitivity/resistance to reovirus in head and neck cancer cell lines.
Oncolytics Biotech Inc. Collaborators Present Translational Brain Cancer Clinical Data and Immunomodulatory Preclinical Research at UK Oncolytic Virus Conference
PR Newswire - Fri Apr 11, 5:30AM CDT
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Alan Melcher, Professor of Clinical Oncology and Biotherapy at the University of Leeds, presented at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Dr. Melcher's presentation, titled "Clinical Virotherapy and Immune Modulation; Bench to Bedside and Back Again," covered early clinical research showing that intravenously delivered REOLYSIN® can cross the blood brain barrier to access tumours in the brains of humans and preclinical research examining the synergies associated with treatment in animal models with GM-CSF prior to administering REOLYSIN®.
Oncolytics Reports Additional Data on Reolysin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 5:30PM CDT
Oncolytics Biotech reported additional encouraging data from the REO 018 study on Reolysin.
Oncolytics Biotech® Inc. Announces Additional Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers
PR Newswire - Tue Apr 08, 5:30AM CDT
Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company" today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN® in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers (REO 018). The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin, paclitaxel and a placebo, while those on the test arm were treated with carboplatin, paclitaxel and REOLYSIN®. Data was available for 165 patients, and was analyzed on an intent-to-treat basis.
Media Advisory - Oncolytics Biotech® Inc. to Participate in 13th Annual Needham Healthcare Conference
CNW Group - Mon Apr 07, 6:00AM CDT
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 13(th) Annual Needham and Company Healthcare Conference in a session on Tuesday April 8(th), 2014 at 9:20 a.m. ET. The conference will take place on April 8(th) and 9(th) in New York, NY.
Oncolytics Biotech Inc. Collaborators to Present Preclinical Research in Multiple Myeloma and Melanoma at AACR 2014 Annual Meeting
CNW Group - Mon Apr 07, 5:30AM CDT
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC) (NASDAQ:ONCY) today announced that research collaborators will make two poster presentations at the American Association for Cancer Research 2014 Annual Meeting. The Meeting is being held from April 6(th) to 9(th), 2014 in San Diego, CA.
Oncolytics Biotech (ONCY) Jumps: Stock Rises 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:57AM CDT
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares rise over 5% on the day.
Oncolytics Biotech® Inc. Announces First Quarter 2014 Results
CNW Group - Thu May 08, 5:30AM CDT
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company"
today announced its financial results and operational highlights for the first quarter ended March 31, 2014. Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Finding People's Purpose In High-Tech Workplaces
at Investor's Business Daily - Wed May 07, 12:43PM CDT
No matter what field you're in, you're in the people business. So says Avner Gal, CEO of Integrity Applications, maker of GlucoTrack, a device that clips onto the ear to measure glucose levels in the blood without pricking the skin. "I am in this...
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Oncolytics Biotech Inc. Collaborators Present Preclinical Research on Liver Cancer at UK Oncolytic Virus Conference
PR Newswire - Mon Apr 14, 5:45AM CDT
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Combined anti-viral and anti-tumour therapy for virus-associated liver cancer," covered preclinical research into the treatment of hepatocellular carcinoma (HCC) associated with infection by Hepatitis B (HBV) and Hepatitis C (HCV). Oncolytics Biotech Inc. Collaborators Present Head and Neck Cancer Biomarker Preclinical Research at UK Oncolytic Virus Conference
PR Newswire - Mon Apr 14, 5:30AM CDT
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC) (NASDAQ:ONCY) today announced that a poster authored by Bolton, et al was presented at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Resistance to oncolytic reovirus is associated with high expression of Yes-Associated Protein (YAP-1) in head and neck cancer," covered preclinical research focused on identifying biomarkers predictive of sensitivity/resistance to reovirus in head and neck cancer cell lines. Oncolytics Biotech Inc. Collaborators Present Translational Brain Cancer Clinical Data and Immunomodulatory Preclinical Research at UK Oncolytic Virus Conference
PR Newswire - Fri Apr 11, 5:30AM CDT
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Alan Melcher, Professor of Clinical Oncology and Biotherapy at the University of Leeds, presented at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Dr. Melcher's presentation, titled "Clinical Virotherapy and Immune Modulation; Bench to Bedside and Back Again," covered early clinical research showing that intravenously delivered REOLYSIN® can cross the blood brain barrier to access tumours in the brains of humans and preclinical research examining the synergies associated with treatment in animal models with GM-CSF prior to administering REOLYSIN®. Oncolytics Reports Additional Data on Reolysin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 5:30PM CDT
Oncolytics Biotech reported additional encouraging data from the REO 018 study on Reolysin.
Oncolytics Biotech® Inc. Announces Additional Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers
PR Newswire - Tue Apr 08, 5:30AM CDT
Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company"
today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN® in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers (REO 018). The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin, paclitaxel and a placebo, while those on the test arm were treated with carboplatin, paclitaxel and REOLYSIN®. Data was available for 165 patients, and was analyzed on an intent-to-treat basis. Media Advisory - Oncolytics Biotech® Inc. to Participate in 13th Annual Needham Healthcare Conference
CNW Group - Mon Apr 07, 6:00AM CDT
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the 13(th) Annual Needham and Company Healthcare Conference in a session on Tuesday April 8(th), 2014 at 9:20 a.m. ET. The conference will take place on April 8(th) and 9(th) in New York, NY.
Oncolytics Biotech Inc. Collaborators to Present Preclinical Research in Multiple Myeloma and Melanoma at AACR 2014 Annual Meeting
CNW Group - Mon Apr 07, 5:30AM CDT
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC) (NASDAQ:ONCY) today announced that research collaborators will make two poster presentations at the American Association for Cancer Research 2014 Annual Meeting. The Meeting is being held from April 6(th) to 9(th), 2014 in San Diego, CA. Oncolytics Biotech (ONCY) Jumps: Stock Rises 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:57AM CDT
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares rise over 5% on the day.
